United States was Integrated Biopharma’s largest region in fiscal 2026, bringing in $35.23M of $43.87M (80%).
| Geography | FY 2012 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $42.62M | $42.34M | $43.63M | $35.23M | |||||||
| Us Customers | — | — | — | — | |||||||
| International Customers | — | — | — | — | |||||||
| Non-Us | $8.06M | $7.97M | $10.73M | $8.64M | |||||||
| Europe & Canada | — | — | — | — | |||||||
| Total | $50.67M | $50.32M | $54.35M | $43.87M |
Integrated Biopharma brought in $43.87M from its two regions in fiscal 2026, the year ended June 30, 2026. That was down 19.3% from $54.35M in fiscal 2025. United States was the largest at $35.23M (80.3%), ahead of Non-Us at $8.64M (19.7%).
Compared with fiscal 2025, United States fell 19.2% to $35.23M and Non-Us fell 19.4% to $8.64M. From fiscal 2023 to 2026, combined revenue from these regions fell from $50.67M to $43.87M, a compound annual decline of 4.7%. United States' share of the total fell from 84.1% to 80.3%.
Contract Manufacturing was Integrated Biopharma’s largest segment in fiscal 2026, bringing in $42.39M of $43.87M (97%).
| Segment | FY 2012 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Contract Manufacturing | $48.28M | $48.57M | $51.68M | $42.39M | |||||||
| Branded Proprietary Products | — | — | — | — | |||||||
| Other Nutraceutical Business | $2.40M | $1.75M | $2.67M | $1.48M | |||||||
| Total | $50.67M | $50.32M | $54.35M | $43.87M |
Integrated Biopharma brought in $43.87M from its two segments in fiscal 2026, the year ended June 30, 2026. That was down 19.3% from $54.35M in fiscal 2025. Contract Manufacturing was the largest at $42.39M (96.6%), ahead of Other Nutraceutical Business at $1.48M (3.4%).
Compared with fiscal 2025, Contract Manufacturing fell 18.0% to $42.39M and Other Nutraceutical Business fell 44.4% to $1.48M. From fiscal 2023 to 2026, combined revenue from these segments fell from $50.67M to $43.87M, a compound annual decline of 4.7%. Contract Manufacturing's share of the total rose from 95.3% to 96.6%.
Integrated Biopharma (INBP) reports its revenue by geography and by segment. In fiscal 2026, United States was its largest region, bringing in $35.23M (80.3% of the total), followed by Non-Us at $8.64M (19.7%).
United States was Integrated Biopharma's largest region in fiscal 2026, bringing in $35.23M, or 80.3% of the $43.87M total across its two regions.
Contract Manufacturing was Integrated Biopharma's largest segment in fiscal 2026, bringing in $42.39M, or 96.6% of the $43.87M total across its two segments.
Every figure comes from Integrated Biopharma's annual financial filings, as reported. Each line keeps the name Integrated Biopharma gives it, and years follow its fiscal calendar.
Integrated Biopharma's revenue by geography goes back to fiscal 2012, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.